BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30442190)

  • 1. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.
    van der Willik KD; Koppelmans V; Hauptmann M; Compter A; Ikram MA; Schagen SB
    Breast Cancer Res; 2018 Nov; 20(1):135. PubMed ID: 30442190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
    Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
    J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive performance in survivors of breast cancer and markers of biological aging.
    Carroll JE; Van Dyk K; Bower JE; Scuric Z; Petersen L; Schiestl R; Irwin MR; Ganz PA
    Cancer; 2019 Jan; 125(2):298-306. PubMed ID: 30474160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late effects of adjuvant chemotherapy for breast cancer on fine motor function.
    Hoogendam YY; Schagen SB; Ikram MA; Boogerd W; Seynaeve C; Seidler RD; Breteler MM; Van der Geest JN; Koppelmans V
    Psychooncology; 2015 Dec; 24(12):1799-807. PubMed ID: 25756497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?
    Ganz PA; Bower JE; Kwan L; Castellon SA; Silverman DH; Geist C; Breen EC; Irwin MR; Cole SW
    Brain Behav Immun; 2013 Mar; 30 Suppl(Suppl):S99-108. PubMed ID: 22884417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
    Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
    Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
    Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer.
    Vardy JL; Stouten-Kemperman MM; Pond G; Booth CM; Rourke SB; Dhillon HM; Dodd A; Crawley A; Tannock IF
    Brain Imaging Behav; 2019 Feb; 13(1):15-26. PubMed ID: 28466438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).
    Bluethmann SM; Alfano CM; Clapp JD; Luta G; Small BJ; Hurria A; Cohen HJ; Sugarman S; B Muss H; Isaacs C; Mandelblatt JS
    Breast Cancer Res Treat; 2017 Oct; 165(3):677-686. PubMed ID: 28653250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
    Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
    J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy.
    Koppelmans V; Schagen SB; Poels MM; Boogerd W; Seynaeve C; van der Lugt A; Breteler MM
    Eur J Cancer; 2011 Nov; 47(17):2531-6. PubMed ID: 21745734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
    J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer.
    Amidi A; Christensen S; Mehlsen M; Jensen AB; Pedersen AD; Zachariae R
    Br J Cancer; 2015 Sep; 113(5):794-801. PubMed ID: 26171932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.